[PDF][PDF] Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
RS Herbst, SG Eckhardt, R Kurzrock, S Ebbinghaus… - 2010 - researchgate.net
RS Herbst, SG Eckhardt, R Kurzrock, S Ebbinghaus, PJ O'Dwyer, MS Gordon, W Novotny…
2010•researchgate.netPurpose Apoptosis ligand 2/tumor necrosis factor–related apoptosis-inducing ligand
(Apo2L/TRAIL)—a member of the tumor necrosis factor cytokine family—induces apoptosis
by activating the extrinsic pathway through the proapoptotic death receptors DR4 and DR5.
Recombinant human Apo2L/TRAIL (rhApo2L/TRAIL) has broad potential as a cancer
therapy. To the best of our knowledge, this is the first in-human clinical trial to assess the
safety, tolerability, pharmacokinetics, and antitumor activity of multiple intravenous doses of …
(Apo2L/TRAIL)—a member of the tumor necrosis factor cytokine family—induces apoptosis
by activating the extrinsic pathway through the proapoptotic death receptors DR4 and DR5.
Recombinant human Apo2L/TRAIL (rhApo2L/TRAIL) has broad potential as a cancer
therapy. To the best of our knowledge, this is the first in-human clinical trial to assess the
safety, tolerability, pharmacokinetics, and antitumor activity of multiple intravenous doses of …
Purpose
Apoptosis ligand 2/tumor necrosis factor–related apoptosis-inducing ligand (Apo2L/TRAIL)—a member of the tumor necrosis factor cytokine family—induces apoptosis by activating the extrinsic pathway through the proapoptotic death receptors DR4 and DR5. Recombinant human Apo2L/TRAIL (rhApo2L/TRAIL) has broad potential as a cancer therapy. To the best of our knowledge, this is the first in-human clinical trial to assess the safety, tolerability, pharmacokinetics, and antitumor activity of multiple intravenous doses of rhApo2L/TRAIL in patients with advanced cancer.
researchgate.net